Claims for Patent: 6,169,079

Summary for Patent: 6,169,079

Title:	Oligonucleotide inhibition of cell adhesion
Abstract:	Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5\'-untranslated sequences, 3\'-untranslated sequences, and intervening sequences. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating cell adhesion proteins with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to one of the foregoing proteins are disclosed. Methods for treatment of diseases responding to inhibition of cell adhesion molecules are disclosed.
Inventor(s):	Bennett; C. Frank (Carlsbad, CA), Mirabelli; Christopher K. (Dover, MA)
Assignee:	Isis Pharmaceuticals Inc. (Carlsbad, CA)
Application Number:	09/128,496
Patent Claims:	1. An antisense oligonucleotide targeted to a transcription initiation site, a translation initiation site, a 5'-untranslated sequence, a coding region or a 3'-untranslated sequence of an mRNA encoding human intercellular adhesion molecule-1. 2. A method of inhibiting the synthesis of human intercellular adhesion molecule-1 in a cell or tissue comprising contacting the cell or tissue with an antisense oligonucleotide of claim 1 and inhibiting the synthesis of human intercellular adhesion molecule-1 in the cell or tissue. 3. A method of treating a human having a disease with an inflammatory component which is modulated by changes in human intercellular adhesion molecule-1 comprising contacting a human with a therapeutically effective amount of an antisense oligonucleotide of claim 1. 4. An antisense oligonucleotide targeted to a 5'-untranslated sequence, a coding region or a 3'untranslated sequence of an mRNA encoding human endothelial leukocyte adhesion molecule-1. 5. A method of inhibiting the synthesis of human endothelial leukocyte adhesion molecule-1 in a cell or tissue comprising contacting the cell or tissue with an antisense oligonucleotide of claim 4 and inhibiting the synthesis of human endothelial leukocyte molecule-1 in the cell or tissue. 6. A method of treating a human having a disease with an inflammatory component which is modulated by changes in human endothelial leukocyte adhesion molecule-1 comprising contacting a human with a therapeutically effective amount of an antisense oligonucleotide of claim 4. 7. An antisense oligonucleotide targeted to a 5'-untranslated sequence, a coding region, an exon/intron junction, a termination codon or a 3'-untranslated sequence of an mRNA encoding human vascular cell adhesion molecule-1. 8. A method of inhibiting the synthesis of vascular cell adhesion molecule-1 in a cell or tissue comprising contacting the cell or tissue with an antisense oligonucleotide of claim 7 and inhibiting the synthesis of vascular cell adhesion molecule-1 in the cell or tissue. 9. A method of treating a human having a disease with an inflammatory component which is modulated by changes in human vascular cell adhesion molecule-1 comprising contacting a human with a therapeutically effective amount of an antisense oligonucleotide of claim 7.

Details for Patent 6,169,079

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2010-08-14
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2010-08-14
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2010-08-14